This information is intended for healthcare professionals based in Ireland. If you are not a healthcare professional in Ireland, click here
HOME / PRESCRIBER CHECKLISTS / OVERVIEW
Overview patient checklist
ELIQUIS® (apixaban) Resources for Healthcare Professionals
Checklist to use when prescribing ELIQUIS to patients with NVAF
Checklist to use when prescribing ELIQUIS to patients with DVT / PE
Checklist to use when prescribing ELIQUIS to patients with NVAF switching from warfarin
ELIQUIS® (apixaban): an oral, direct factor Xa inhibitor — is indicated for:
- Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation, with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥II)1
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults1
- Prevention of Venous Thromboembolic Event (VTE) in adult patients who have undergone elective hip or knee replacement surgery1
ELIQUIS (apixaban) is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II); treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults; and, prevention of VTE in adult patients who have undergone elective hip or knee replacement surgery.1
Footnotes:
DVT = Deep Vein Thrombosis NVAF = Non-Valvular Atrial Fibrillation NYHA = new York Heart Association PE = Pulmonary Embolism TIA = Transient Ischaemic Attack VTE = Venous Thromboembolic Event
References:
- ELIQUIS® (apixaban) Summary of Product Characteristics.
Date of Preparation: August 2023 | Job Description: 432-IE-2300030